SynthesisBMC pediatrics2024
Risk factors for complications of Mycoplasma pneumoniae pneumonia in hospitalized children in China: a systematic review and meta-analysis.
Synthesis in BMC pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neutrophil-to-lymphocyte ratio for predicting disease severity and outcomes in children with Mycoplasma pneumoniae pneumonia: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Associations of Serum CIRP and CXCL5 With Prognosis and Neutrophil Extracellular Traps in Pediatric Mycoplasma pneumoniae Pneumonia.The clinical respiratory journal · 2026Article
- Risk factors associated with pleural effusion in pediatric patients with severe Mycoplasma pneumonia.Medicine · 2026Observational
- Development and validation of a multivariate predictive model for the risk of refractory mycoplasma pneumoniae pneumonia in children based on quantitative computed tomography features.Translational pediatrics · 2026Article
- Novel inflammatory biomarkers and disease severity in hospitalized children withTranslational pediatrics · 2026Article
- Correlation analysis of serum CHI3L1, HMGB1, and CD62E detection with the prognosis of Mycoplasma pneumoniae in children.Journal of medical biochemistry · 2026Article
- [Trends, predictions, and etiological characteristics of the incidence and mortality of lower respiratory infections among children under 14 years in China from 1990 to 2021].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Study on the value and mechanism of miR-369-5p in childhood pneumonia.BMC immunology · 2026Article
- Independent risk factors and predictive model for high hospitalization costs in children with Mycoplasma pneumoniae pneumonia.BMC pediatrics · 2026Article
- Blood-based inflammatory parameters and machine learning models for mortality prediction in critically ill pediatric pneumonia: a retrospective cohort study.Translational pediatrics · 2026Article
- MIR210HG promotes the progression of pediatric pneumonia by inducing apoptosis and inflammation through downregulating miR-195-5p and upregulating FGF2.BMC pediatrics · 2026Article
- Epidemiological characteristics of Mycoplasma pneumoniae in hospitalized children before during and after the COVID-19 pandemic in xi'an China.Scientific reports · 2026Article
- Age and hypoalbuminemia independently predict pulmonary consolidation in children with 23S rRNA A2063G-mutantFrontiers in pediatrics · 2026Article
- Admission-time immunologic patterns in hospitalized children withFrontiers in pediatrics · 2026Article
- Development of a nomogram to predict acute liver injury in children withFrontiers in pediatrics · 2026Article
- Immune dysregulation inFrontiers in immunology · 2026Review
- Clinical and epidemiological profiles of six respiratory pathogens in hospitalized children in Lixin County, Anhui, China (2024-2025).Frontiers in pediatrics · 2026Article
- Development of a Prediction Model for Severe PediatricInfection and drug resistance · 2026Article
- Serum HMGB3 and PCSK9 Levels as Predictors of Early Treatment Response in PediatricInternational journal of general medicine · 2026Article
- Clinical characteristics analysis of pertussis and Mycoplasma pneumoniae infection in children.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycoplasma pneumoniae pneumonia (MPP) is a common respiratory disease in children. Some patients may develop long-term respiratory issues such as chronic cough and wheezing due to complications. These complications increase the health burden for children with MPP, highlighting the need to understand their risk factors in order to improve disease prognosis. This study aims to assess the risk factors for complications in hospitalized children with MPP in China.
methodsA comprehensive review of Chinese and English databases was conducted up to April 2024 to retrieve studies focusing on complications in hospitalized children with MPP. Pooled effect sizes were calculated using random-effects or fixed-effects models. Statistical analyses were performed using R software and RevMan 5.3.
resultsThis meta-analysis encompassed a total of 17 studies. We analyzed multiple risk factors associated with complications, including prolonged fever (OR: 3.79, aOR: 1.64), pleural effusion (OR: 3.71, aOR: 6.70), extensive lung infiltration (OR: 5.52, aOR: 3.57), ≥ 2/3 consolidation in a single lung lobe (OR: 4.29, aOR: 4.52), right upper lung lesion (OR: 4.84, aOR: 3.57), extrapulmonary manifestations (OR: 3.20, aOR: 1.89), hypoxemia (OR: 7.58, aOR: 12.43), delayed administration of glucocorticoids (OR: 7.93, aOR: 6.67), and delayed administration of macrolides (OR: 2.75, aOR: 3.84).
conclusionHospitalized children with SMPP and RMPP may have a higher risk of complications, and it is important to identify risk factors early and provide appropriate treatment to minimize complications. The current level of evidence is relatively low and may not accurately reflect the actual clinical situation in China. Further high-quality studies are needed to validate and clarify these findings.
trial registrationOur protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (registration number: CRD42024534397).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.